Trem2 Microglial Signaling Pathway In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) is a critical receptor expressed primarily on microglia in the central nervous system. It plays a central role in regulating microglial function, amyloid clearance, and neuroinflammation. TREM2 variants are major genetic risk factors for Alzheimer's disease, making it a promising therapeutic target.
flowchart TD
subgraph TREM2_Structure
A[TREM2<br>Extracellular Domain] --> B[Transmembrane<br>Domain] -->
B --> C[Intracellular<br>Tail] -->
A1[Ligand Binding<br>Site] -.-> A
style A fill:#98FB98
style B fill:#87CEEB
style C fill:#DDA0DD
end
subgraph TREM2_Variants
R47H -.-> A
R62H -.-> A
T66M -.-> A
H157Y -.-> A
end
TREM2 is a type I transmembrane protein with:
- Extracellular domain: Ig-like V-type domain for ligand binding
- Transmembrane domain: Connects to signaling adapter DAP12
- Intracellular tail: Short cytoplasmic domain with no intrinsic signaling motif
flowchart TD
subgraph Ligands
A[Amyloid Beta] --> TREM2
B[Lipids] --> TREM2
C[Apolipoproteins<br>E/ApoJ] --> TREM2
D[Phosphatidylserine] --> TREM2
end
TREM2 --> DAP12[DAP12<br>TYROBP] -->
DAP12 --> SYK[SYK Kinase] -->
SYK --> PLCG2[PLCγ2] -->
PLCG2 --> DAG[DAG/PKC] -->
PLCG2 --> IP3[IP3/Ca2+] -->
DAG --> MAPK[MAPK Pathway] -->
IP3 --> NFAT[NFAT Transcription] -->
MAPK --> NFKB[NF-κB)
NFAT --> GeneExp[Gene Expression] -->
NFKB --> GeneExp
- DAP12 (TYROBP): ITAM-containing adaptor protein
- DAP10 (TREM2 variant): Can pair with TREM2 in some contexts
- SYK: Primary kinase activated
- PLCγ2: Phospholipase C gamma 2
- VAV: Guanine nucleotide exchange factors
- ERK, p38, JNK: MAPK pathway components
¶ TREM2 Ligands in Neurodegeneration
Aβ oligomers and fibrils can bind to TREM2, triggering:
- Microglial phagocytosis
- Cytokine production
- Cell survival signaling
¶ Lipids and Apolipoproteins
TREM2 acts as a lipid receptor:
- ApoE (particularly ApoE4 isoform)
- ApoJ (clusterin)
- Phospholipids暴露 on damaged cells
Externalized phosphatidylserine on apoptotic cells serves as a "eat-me" signal recognized by TREM2.
¶ TREM2 Variants and Alzheimer's Risk
flowchart TD
subgraph TREM2_Risk_Variants
R47H[rs75932628<br>R47H] --> High[~3x AD Risk] -->
R62H[rs143332484<br>R62H] --> Moderate[~1.5x AD Risk] -->
T66M[rs28937816<br>T66M] --> Moderate[~2x AD Risk] -->
H157Y[rs2234253<br>H157Y] --> Moderate[~1.5x AD Risk]
end
High --> Impaired[Impaired Ligand Binding] -->
Moderate --> Impaired
Impaired --> Dysfunction[Microglial Dysfunction]
| Variant |
Effect on TREM2 Function |
AD Risk Increase |
| R47H |
Reduced Aβ binding |
~3-fold |
| R62H |
Altered lipid binding |
~1.5-fold |
| T66M |
Impaired folding/ trafficking |
~2-fold |
| H157Y |
Reduced signaling |
~1.5-fold |
flowchart TD
subgraph Stage_1_DAM
Homeostatic[Homeostatic<br>Microglia] --> EarlyDAM[Early DAM] -->
EarlyDAM --> TREM2[TREM2<br>Activation] -->
EarlyDAM --> Tyrobp[DAP12<br>Signaling]
end
subgraph Stage_2_DAM
TREM2 --> FullDAM[Full DAM] -->
Tyrobp --> FullDAM
end
subgraph DAM_Features
FullDAM --> Phag[Enhanced<br>Phagocytosis] -->
FullDAM --> Inflam[Pro-inflammatory<br>Response] -->
FullDAM --> Repair[Damage<br>Repair]
end
style Homeostatic fill:#90EE90
style EarlyDAM fill:#FFD700
style FullDAM fill:#FF6B6B
TREM2 is required for the transition from homeostatic microglia to the disease-associated microglia (DAM) phenotype:
- Downregulation of homeostatic markers (P2ry12, Cx3cr1)
- Upregulation of Apoe, Hexb
- Full activation requires functional TREM2
- Upregulation of lipid metabolism genes
- Phagocytic activation
- Production of inflammatory mediators
TREM2-mediated phagocytosis:
- Engulfs Aβ plaques
- Targets plaques for lysosomal degradation
- Prevents plaque spread
TREM2 deficiency leads to:
- Reduced microglial clustering around plaques
- Increased plaque burden
- Accelerated disease progression
TREM2 signaling has complex effects on neuroinflammation:
Pro-inflammatory effects:
- Activates NF-κB
- Induces cytokine production (IL-1β, TNF-α)
Anti-inflammatory effects:
- Promotes resolution
- Enhances debris clearance
- Supports tissue repair
TREM2 plays a dual role in synaptic remodeling:
- Physiological: Removes inappropriate synapses during development
- Pathological: May contribute to synaptic loss in AD when dysregulated
Although primarily studied in AD, TREM2 also affects PD:
- Genetic association: TREM2 variants modify PD risk
- α-Synuclein clearance: TREM2 can recognize and clear α-synuclein aggregates
- Neuroinflammation: Regulates microglial responses to dopaminergic neuron damage
- Mitochondrial function: Affects microglial metabolic fitness
| Antibody |
Company |
Stage |
Mechanism |
| AL002 |
Alector/AbbVie |
Phase 2 |
TREM2 agonist |
| AL003 |
Alector |
Phase 1 |
TREM2 agonist |
| SHR-1707 |
Jiangsu Hengrui |
Phase 1 |
TREM2 bispecific |
- Lipid-based agonists targeting the extracellular domain
- Allosteric modulators enhancing TREM2 signaling
- AAV-mediated TREM2 overexpression
- CRISPR-based approaches to correct risk variants
- sTREM2: Soluble TREM2 in CSF (reflects microglial activation)
- CSF cytokines: IL-1β, TNF-α (inflammation markers)
- PET imaging: Microglial activation markers (TSPO)
The study of Trem2 Microglial Signaling Pathway In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
Deczkowska A, et al. TREM2 as a regulator of microglial aging and neurodegeneration. Nat Neurosci. 2024.
-
Ulrich JD, et al. TREM2 and the amyloid response. Nat Rev Neurosci. 2023.
-
Wang Y, et al. TREM2 deficiency leads to impaired microglial function. Cell. 2023.
-
Song WM, et al. Human TREM2 variants and Alzheimer's disease risk. Neuron. 2024.
-
Lee CYD, et al. TREM2 in Parkinson's disease. Nat Rev Neurol. 2025.
-
Alector Inc. AL002 clinical trial data. 2024-2025.
-
Schoch KM, et al. TREM2-targeted antibodies for neurodegeneration. Nat Rev Drug Discov. 2024.
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
7 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
33% |
| Mechanistic Completeness |
50% |
Overall Confidence: 32%